

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3753802

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HONGQI TIAN	11/18/2014
CONGHUI JI	11/16/2014
CHUNLEI LIU	11/05/2014
LI KONG	11/11/2014
YING CHENG	10/31/2014
GONGCHAO HUANG	11/13/2014
RECEIVING PARTY DATA	
Name:	TIANJIN BINJIANG PHARMA, INC.
Street Address:	N1701, #220 DONGTING ROAD
Internal Address:	TIANJIN ECONOMIC TECHNOLOGY DEVELOPMENT AREA
City:	TIANJIN
State/Country:	CHINA
Postal Code:	300457
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15050045
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	650-813-5752
Email:	rlang@mofo.com
Correspondent Name:	ZONG-QIANG BILL TIAN
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	755 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1018
ATTORNEY DOCKET NUMBER:	744142000110
NAME OF SUBMITTER:	ZONG-QIANG BILL TIAN
SIGNATURE:	/ Zong-Qiang Bill Tian /
DATE SIGNED:	02/24/2016

PATENT

Total Attachments: 3

source=74414_20001_10_Assignment_2#page1.tif

source=74414_20001_10_Assignment_2#page2.tif

source=74414_20001_10_Assignment_2#page3.tif

ASSIGNMENT

This assignment is by:

1. Hongqi TIAN (田红旗)
c/o Tianjin Binjiang Pharma, Inc.
N1701, #220 Dongting Road, TEDA
Tianjin 300457, China
2. Conghui JI (季聪慧)
c/o Tianjin Binjiang Pharma, Inc.
N1701, #220 Dongting Road, TEDA
Tianjin 300457, China
3. Chunlei LIU (刘春磊)
c/o Tianjin Binjiang Pharma, Inc.
N1701, #220 Dongting Road, TEDA
Tianjin 300457, China
4. Li KONG (孔刚)
c/o Tianjin Binjiang Pharma, Inc.
N1701, #220 Dongting Road, TEDA
Tianjin 300457, China
5. Ying CHENG (程瑛)
c/o Tianjin Binjiang Pharma, Inc.
N1701, #220 Dongting Road, TEDA
Tianjin 300457, China
6. Gongchao HUANG (黄功超)
c/o Tianjin Binjiang Pharma, Inc.
N1701, #220 Dongting Road, TEDA
Tianjin 300457, China

(referred to in this Assignment as "Assignors"), who reside at or have a mailing address as listed above.

This Assignment is to:

Tianjin Binjiang Pharma, Inc.
(天津滨江药物研发有限公司)
N1701, #220 Dongting Road, Tianjin Economic Technology Development Area,
Tianjin 300457, China
A corporation duly organized under and pursuant to the laws of: P. R. China

(referred to in this Assignment as "Assignee"), who desires to acquire Assignors' entire right, title and interest in the International Application filed via the Patent Cooperation Treaty (hereinafter referred to as "PCT application") and US application set forth below and in said inventions set forth therein, and in any United States or foreign, letters patent or patents, to be obtained therefor and thereon.

Assignors have invented certain new and useful inventions in:

BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF

for which the following PCT and US applications have been filed.

Serial No.: PCT/CN2013/000037 Filing Date: January 16, 2013

Serial No.: 14/372,731 Filing Date: January 16, 2013 (Int'l)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged.

1. Assignors hereby sell, assign, transfer and set over, to Assignee, its successors, legal representatives and assigns, Assignors' entire right, title and interest in and to the above-mentioned inventions, PCT application, US application for letters patent, and any application for letters patent claiming priority thereto, and any and all letters patent or patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all provisionals, national stage applications, divisions, continuations, continuations-in-part and substitutions of said application, or reissues, re-examinations or extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

2. Assignors represent, warrant and covenant that, at the time of execution and delivery of this agreement, Assignors are the sole and lawful owners of Assignors' entire right, title and interest in and to said inventions and said application for letters patent, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement.

3. Assignors shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) letters patent for said inventions in any country, including any reissue, re-examination or extension of or interference proceedings; or (c) any provisional, division, continuation, continuation-in-part, or substitutions of any application for letters patent or any reissues, re-examinations, extensions or interference proceedings involving any letters patent, to be obtained thereon. To be clear, for purposes of this paragraph, "desirable" shall include, without limitation, any act necessary or useful in connection with United States laws and/or international conventions.






4. Assignors hereby authorize and request the Commissioner of Patents in the United States to issue the above mentioned letters patents of the United States to Assignee as the assignee of said

inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.


5. "I hereby grant Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known."

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

Assignor:

Date: <u>Nov. 18, 2014</u>	Signature: <u></u> Hongqi Tian
Date: <u>NOV. 16, 2014</u>	Signature: <u></u> Conghui Ji
Date: <u>NOV. 5, 2014</u>	Signature: <u></u> Chunlei Liu
Date: <u>NOV. 11, 2014</u>	Signature: <u></u> Li Kong
Date: <u>Oct. 31, 2014</u>	Signature: <u></u> Ying Cheng
Date: <u>NOV. 13, 2014</u>	Signature: <u></u> Gongchao Huang

Assignee:

Date: <u>Nov. 18, 2014</u>	Signature: <u></u> Hongqi Tian, President Tianjin Binjiang Pharma, Inc.
----------------------------	---